金域医学公告称，2026年1月5日公司第四届董事会第九次会议审议通过预计与金圻睿2026年度日常关联 交易的议案。2025年公司预计与金圻睿交易2.40亿元，1 - 11月累计已发生交易2.21亿元。2026年预计交 易2.22亿元，其中向其采购商品预计2.20亿元，占同类业务不超15%；向其提供劳务预计150万元，占同 类业务不超5%。金圻睿为佳鉴公司全资子公司，因股东关联关系被认定为关联人，其财务指标正常， 履约能力良好。 ...

美年健康公告，公司于2025年12月31日收到深圳证券交易所的通知，因公司本次交易申请文件中记载的 财务资料已过有效期，需要补充提交，按照《深圳证券交易所上市公司重大资产重组审核规则》的相关 规定，深交所对公司本次交易中止审核。 ...

近年来，三河市始终把科技创新作为高质量发展的核心引擎，紧扣京津冀协同发展战略，持续优化科创 生态，完善政策扶持体系，全力支持企业建设高水平创新平台，深化产学研协同创新，推动创新链、产 业链、资金链、人才链深度融合。截至目前，三河市省级创新平台数量稳步增长，覆盖新材料、高端装 备、大健康、工程技术等多个重点领域，获批省、市级研发平台总数位居廊坊市首位，形成了"培育一 批、认定一批、壮大一批"的良性发展格局，创新能级持续提升，成为驱动产业转型升级的核心载体。 三河市将持续强化精准服务与政策赋能，全力支持新获批省级技术创新中心和重点实验室建好平台、引 育人才，鼓励企业加大研发投入，加速科技成果转化应用。以省级创新平台为抓手，辐射带动更多企业 投身创新实践，为建设京津冀协同创新示范区、打造高质量发展标杆城市注入源源不断的科创动能。 来源：廊坊日报 近日，河北省科学技术厅公布了2025年新建省重点实验室和省技术创新中心名单，三河市创新驱动发展 再传捷报，亮克威泽工业涂料有限公司、河北华勘地质勘查有限公司成功获批省级技术创新中心，河北 燕达医院、华北科技学院顺利通过省级重点实验室认定。4家企业同步跻身省级高端创新平台，彰 ...

Core Viewpoint - The article discusses the rising trend of foreign patients traveling to China for medical treatment, highlighting the efficiency and cost-effectiveness of the Chinese healthcare system compared to Western countries, particularly the UK and the US [3][10][27]. Group 1: Case Studies of Foreign Patients - A British TikTok influencer named Amy traveled 8,000 kilometers to China for medical treatment, receiving a comprehensive diagnosis and treatment within 13 days at a cost of approximately 2,800 RMB (298.6 GBP), significantly lower than the costs in the UK [4][5]. - Another case involved a British blogger whose stepfather faced long wait times for diagnosis in the UK, ultimately receiving prompt treatment in Shanghai, which was also documented on social media [8][9]. Group 2: Factors Driving Interest in Medical Tourism - The increase in foreign patients seeking treatment in China is partly due to recent visa exemption policies and the comparative analysis of healthcare costs between China and Western countries, which revealed significant savings for patients [10][20]. - Social media has played a crucial role in spreading awareness about the efficiency and affordability of Chinese healthcare, leading to a surge in interest from foreign patients [6][11]. Group 3: Concerns from Domestic Patients - There are concerns among Chinese citizens about foreign patients potentially monopolizing medical resources, especially in top-tier hospitals that are already under strain [12][14]. - Some citizens worry that the influx of foreign patients could lead to a diversion of resources away from local patients, creating a perception of inequality in healthcare access [15][16]. Group 4: Structure of International Medical Services - Chinese hospitals have established dedicated international medical departments that operate independently from regular outpatient services, ensuring that domestic patients are not adversely affected [18][19]. - The international medical departments are subject to strict regulations, limiting their service capacity to 10% of the total hospital services, thereby safeguarding local patient access [20][21]. Group 5: Future Prospects and Developments - The Chinese healthcare system is actively preparing to attract more foreign patients, with many hospitals establishing international medical departments and engaging with potential patients through social media [23][24]. - Recent government initiatives aim to standardize and promote international medical services, indicating a strategic push to enhance China's position in the global medical tourism market [25][26][27].

格隆汇1月5日丨合富中国(603122.SH)在投资者互动平台表示,目前公司业务重心聚焦于大中华市场,服务 客户主要为大陆及中国台湾的医疗机构,并将自身定位为"医院高质量发展伙伴",公司的业务范围暂不涉 及欧盟国家。公司管理团队始终密切关注行业发展趋势,积极寻求新项目合作、投资等合作扩能机会,助 力业务区域覆盖,以期实现长期可持续成长,为广大投资者创造长期投资价值。 ...

Core Viewpoint - The case of Dr. Li Jianhua from Guangzhou Aier Eye Hospital against online influencer Chen Mou for defamation highlights the importance of protecting citizens' reputation rights and reflects the government's ongoing efforts to strengthen online governance and punish cyber crimes [1][5]. Group 1: Case Background - Dr. Li Jianhua was subjected to online harassment by Chen Mou, who began spreading defamatory statements about him on social media after a medical dispute involving another party [1]. - Chen Mou published hundreds to thousands of defamatory posts from July 2021, falsely accusing Dr. Li of "academic fraud" and "practicing medicine without a license," leading to severe personal and professional consequences for Dr. Li [1][2]. Group 2: Legal Proceedings - After unsuccessful attempts to resolve the issue amicably, Dr. Li filed a civil lawsuit in November 2021, which resulted in court rulings against Chen Mou for infringing on Dr. Li's reputation and image rights [2][3]. - Despite the civil court's decisions, Chen Mou continued to spread false information, further damaging Dr. Li's reputation and undermining public trust in the judicial system [2]. Group 3: Criminal Charges and Sentencing - Dr. Li decided to pursue criminal charges against Chen Mou, leading to a conviction for defamation, with the court finding that Chen Mou's actions met the criteria for serious defamation as defined by legal standards [4][5]. - The court sentenced Chen Mou to one and a half years in prison, emphasizing the severity of his actions and the need for accountability in online spaces [5]. Group 4: Implications for Online Governance - This case serves as a significant precedent in combating online defamation and reinforces the message that the internet is not a lawless space, urging citizens to respect the legal boundaries of free speech [6]. - The Chinese government has been actively enhancing online governance through various laws and regulations aimed at curbing online infringement and violence, with new laws set to take effect in 2026 to further address these issues [5][6].

为加快建立全国统一的医疗服务真实世界医保综合价值评价体系，根据《关于开展真实世界医保综合价 值评价试点工作的通知》（医保办发〔2025〕15号）有关要求，我们研究起草了《医疗服务真实世界医 保综合价值评价管理指南（试行）》，现向社会公开征求意见。公众可以书面或电子邮件的形式向我局 反馈意见，意见反馈截止时间为2026年1月16日17：00。 电子邮箱：jczxylc@nhsa.gov.cn 通讯地址：北京市西城区月坛北小街甲2号国家医疗保障局医药价格和招标采购指导中心，邮编： 100830 附件：医疗服务真实世界医保综合价值评价管理指南（试行） 国家医疗保障局 2026年1月5日 本指南所称医疗服务价格项目全生命周期主要包括预立项、 项目新增、项目转归、医保目录调整、项目废止、价格制定与动 态调整等场景。医疗服务真实世界医保综合价值评价旨在为不同 场景下的医保决策提供循证证据,为新技术新方法新产品铺就一 条从"概念-实验室产品=医保预备立项=医保验证-医保立项 - 医保评价-医保付费"的渐进式产业升级和医保支付引领科技 创新之路。 具体而言,在项目新增阶段,通过评价识别尚未满足临床需 求、具有潜在价值的创新医 ...

Group 1: Pharmaceutical and Biotech Industry - The pharmaceutical and biotech industry in China is entering a new era of innovative drugs, transitioning from a generics-dominated market (pre-2018) to a focus on innovation from 2026 onwards, with significant growth expected in innovative drug development and commercialization [5] - The report highlights the importance of monitoring the launch rhythm of innovative drugs, competitive landscape, and key clinical data in 2026, as well as the impact of international business development (BD) transactions on cash flow [5] - The CXO and upstream scientific reagent sectors are expected to benefit from the rapid development of innovative drugs, maintaining a strong growth momentum [5] Group 2: Medical Device Industry - The medical device industry has faced significant challenges over the past three years, including anti-corruption measures and price reductions, leading to a decline in profitability for listed companies [6] - However, since 2025, there has been a gradual recovery in the industry, with improved profitability expected in 2026 as negative factors clear and new technologies like brain-computer interfaces and AI products emerge [6] - The overseas market is anticipated to become a new growth point due to companies' investments in capacity, channels, and branding [6] Group 3: Medical Services Consumption - The medical services consumption sector has been under pressure from macroeconomic conditions and policy changes, but is expected to recover as domestic consumption gradually improves [7] - The report emphasizes the potential for specialized hospitals with brand and chain advantages to lead growth in 2026, alongside the retail service market benefiting from the diversification of services [7] - A list of recommended stocks includes companies like Kelun Pharmaceutical, Rongchang Bio, and Yifeng Pharmacy, which are positioned to capitalize on these trends [7] Group 4: Manufacturing PMI Insights - The manufacturing PMI for December 2025 was reported at 50.1%, indicating a recovery from the previous value of 49.2%, driven by improved demand and supply conditions [10][11] - Factors contributing to this increase include positive expectations from recent important meetings, a recovery in trade relations, and increased pre-holiday inventory demands [10][12] - High-tech manufacturing sectors showed significant growth, with the high-tech PMI reaching 52.5%, indicating strong performance in this segment [13] Group 5: Economic Policy and Market Outlook - The central economic work conference has set a positive tone for 2026, emphasizing the importance of domestic demand and investment stabilization [15] - The report suggests that upcoming policies will focus on enhancing consumer spending and investment, with potential adjustments in housing policies expected to support the market [15] - The market is advised to focus on sectors benefiting from technological advancements and domestic consumption trends, particularly in light of anticipated policy support [16]

Group 1 - The high-pressure oxygen chamber concept has seen a significant increase of 7.01%, ranking second among concept sectors, with 10 stocks rising, including BeiYikang which hit a 30% limit up, and others like International Medicine and Innovation Medical also reaching their limit up [1] - The main inflow of funds into the high-pressure oxygen chamber concept amounted to 389 million yuan, with Innovation Medical receiving the highest net inflow of 256 million yuan, followed by International Medicine and Yingkang Life [2][3] - The net inflow ratios for major stocks in the high-pressure oxygen chamber concept are led by Innovation Medical at 74.84%, International Medicine at 41.60%, and Yingkang Life at 8.97% [3] Group 2 - The top-performing concept sectors today include Brain-Computer Interface with a rise of 13.70%, while the Free Trade Zone saw a decline of 2.93% [2] - Other notable sectors include Blood Oxygen Meters up 5.65% and 2025 Annual Report Pre-Increase up 5.16% [2] - The trading volume and turnover rates for stocks in the high-pressure oxygen chamber concept indicate active trading, with Innovation Medical showing a turnover rate of 3.48% [3]

证券之星消息，1月5日医疗服务板块较上一交易日上涨4.77%，三博脑科领涨。当日上证指数报收于 4023.42，上涨1.38%。深证成指报收于13828.63，上涨2.24%。医疗服务板块个股涨跌见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 603127 | 昭衍新药 | 2.35 Z | 22.74% | -9686.88万 | -9.38% | -1.38 Z | -13.36% | | 301293 | 三博脑科 | 2.14 乙 | 28.28% | -1.36亿 | -18.04% | -7732.79万 | -10.24% | | 603259 | 药明康德 | 1.81 Z | 2.63% | -3.71 乙 | -5.39% | 1.90 Z | 2.76% | | 002173 | 创新医疗 | 1.76 Z | 51.25% | -9072.19万 | -26.48% | -8486 ...